Legal & General Group
SRPT icon

Legal & General Group’s Sarepta Therapeutics SRPT Stock Holding History

Legal & General Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Buy
877,627
+10,884
+1% +$206K ﹤0.01% 981
2026
Q1 		$18.9M Buy
866,743
+602,286
+228% +$11.7M ﹤0.01% 844
2025
Q4 		$5.69M Sell
264,457
-2,105
-0.8% -$44.4K ﹤0.01% 1490
2025
Q3 		$5.14M Buy
266,562
+31,752
+14% +$566K ﹤0.01% 1564
2025
Q2 		$4.02M Buy
234,810
+26,540
+13% +$1.13M ﹤0.01% 1650
2025
Q1 		$13.3M Buy
208,270
+56,914
+38% +$5.99M ﹤0.01% 990
2024
Q4 		$18.4M Buy
151,356
+8,494
+6% +$1.04M ﹤0.01% 856
2024
Q3 		$17.8M Buy
142,862
+3,691
+3% +$510K ﹤0.01% 885
2024
Q2 		$22M Buy
139,171
+50,289
+57% +$6.46M 0.01% 802
2024
Q1 		$11.5M Buy
88,882
+757
+0.9% +$92.7K ﹤0.01% 1069
2023
Q4 		$8.5M Sell
88,125
-4,416
-5% -$424K ﹤0.01% 1223
2023
Q3 		$11.2M Buy
92,541
+1,364
+1% +$154K ﹤0.01% 1016
2023
Q2 		$10.4M Sell
91,177
-8,627
-9% -$1.11M ﹤0.01% 1087
2023
Q1 		$13.8M Buy
99,804
+18,757
+23% +$2.43M ﹤0.01% 928
2022
Q4 		$10.5M Buy
81,047
+3,113
+4% +$361K ﹤0.01% 1042
2022
Q3 		$8.62M Sell
77,934
-14,027
-15% -$1.41M ﹤0.01% 1098
2022
Q2 		$6.89M Buy
91,961
+110
+0.1% +$8.09K ﹤0.01% 1266
2022
Q1 		$7.18M Buy
91,851
+4,816
+6% +$369K ﹤0.01% 1334
2021
Q4 		$7.84M Buy
87,035
+857
+1% +$73.3K ﹤0.01% 1332
2021
Q3 		$7.97M Sell
86,178
-140,315
-62% -$10.8M ﹤0.01% 1294
2021
Q2 		$17.6M Sell
226,493
-186,870
-45% -$14.2M 0.01% 930
2021
Q1 		$30.8M Buy
413,363
+7,007
+2% +$647K 0.01% 767
2020
Q4 		$69.3M Sell
406,356
-2,275
-0.6% -$337K 0.03% 574
2020
Q3 		$57.4M Buy
408,631
+146,219
+56% +$22.2M 0.03% 560
2020
Q2 		$42.1M Buy
262,412
+11,264
+4% +$1.53M 0.02% 615
2020
Q1 		$24.6M Buy
251,148
+21,251
+9% +$2.43M 0.01% 685
2019
Q4 		$29.7M Buy
229,897
+51,076
+29% +$5.16M 0.01% 718
2019
Q3 		$13.5M Buy
178,821
+139,836
+359% +$16.5M 0.01% 888
2019
Q2 		$5.92M Buy
38,985
+1,554
+4% +$189K ﹤0.01% 1202
2019
Q1 		$4.46M Buy
37,431
+2,314
+7% +$297K ﹤0.01% 1253
2018
Q4 		$3.83M Buy
35,117
+5,878
+20% +$735K ﹤0.01% 1216
2018
Q3 		$4.72M Buy
29,239
+1,074
+4% +$147K ﹤0.01% 1210
2018
Q2 		$3.72M Buy
28,165
+3,085
+12% +$291K ﹤0.01% 1312
2018
Q1 		$1.86M Sell
25,080
-1,283
-5% -$85.6K ﹤0.01% 1648
2017
Q4 		$1.47M Buy
26,363
+1,967
+8% +$104K ﹤0.01% 1745
2017
Q3 		$1.12M Buy
24,396
+6,806
+39% +$272K ﹤0.01% 1823
2017
Q2 		$593K Buy
17,590
+663
+4% +$21.6K ﹤0.01% 2012
2017
Q1 		$498K Sell
16,927
-222
-1% -$6.87K ﹤0.01% 2037
2016
Q4 		$471K Buy
17,149
+7,796
+83% +$313K ﹤0.01% 1993
2016
Q3 		$567K Buy
9,353
+2,161
+30% +$65.3K ﹤0.01% 1636
2016
Q2 		$132K Hold
7,192
– – ﹤0.01% 1952
2016
Q1 		$144K Sell
7,192
-190
-3% -$3.32K ﹤0.01% 1850
2015
Q4 		$288K Hold
7,382
– – ﹤0.01% 1587
2015
Q3 		$231K Hold
7,382
– – ﹤0.01% 1637
2015
Q2 		$215K Buy
7,382
+1,417
+24% +$29K ﹤0.01% 1712
2015
Q1 		$82K Hold
5,965
– – ﹤0.01% 2171
2014
Q4 		$87K Hold
5,965
– – ﹤0.01% 2082
2014
Q3 		$126K Buy
+5,965
New +$135K ﹤0.01% 1755

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Legal & General Group's SRPT Position: Q2 2026 in Review

Legal & General Group increased its Sarepta Therapeutics (SRPT) stake by 1.3% in Q2 2026, buying an estimated $206K and bringing the position to 877,627 shares worth $15.8M. The position accounts for ﹤0.01% of the portfolio, ranked #981.

Legal & General Group first reported a position in SRPT in Q3 2014 and has held it in 48 quarters since. The position peaked at $69.3M in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Legal & General Group held 877,627 shares of Sarepta Therapeutics worth $15.8M as of Q2 2026.
  • Legal & General Group bought 10,884 Sarepta Therapeutics shares in Q2 2026, an estimated $206K.
  • Sarepta Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #981 holding.
  • Legal & General Group first reported a position in Sarepta Therapeutics in Q3 2014 and has held it in 48 quarters since.
  • Legal & General Group's Sarepta Therapeutics position peaked at $69.3M in Q4 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.